Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab

F Tato, J Rieger, U Hoffmann - International angiology, 2005 - search.proquest.com
Abstract Treatment of Takayasu's arteritis remains a demanding challenge to clinicians. In
many patients the course of the disease is characterized by frequent relapses and disease …
被引用次数：80 相关文章

[引用][C] Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab

F TATO, J RIEGER, U HOFFMANN - International angiology, 2005 - pascal-francis.inist.fr
Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor
necrosis factor antibody adalimumab CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab

F Tatò, J Rieger, U Hoffmann - … angiology: a journal of …, 2005 - pubmed.ncbi.nlm.nih.gov
Treatment of Takayasu's arteritis remains a demanding challenge to clinicians. In many
patients the course of the disease is characterized by frequent relapses and disease …

Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab.

F Tatò, J Rieger, U Hoffmann - … : a Journal of the International Union …, 2005 - europepmc.org
Treatment of Takayasu's arteritis remains a demanding challenge to clinicians. In many
patients the course of the disease is characterized by frequent relapses and disease …

Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab

F TATÒ, J RIEGER, U HOFFMANN - International Angiology, 2005 - minervamedica.it
Treatment of Takayasu's arteritis remains a demanding challenge to clinicians. In many
patients the course of the disease is characterized by frequent relapses and disease …

[引用][C] Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab

F TATO, J RIEGER, U HOFFMANN - International angiology, 2005 - Minerva Medica